Clinical Report: Evaluation of Efgartigimod in Guillain–Barré Syndrome
Overview
This retrospective study evaluates the clinical efficacy and safety of efgartigimod in patients with Guillain–Barré syndrome (GBS).
Background
Guillain–Barré syndrome (GBS) is a severe autoimmune neuropathy with limited treatment options, necessitating the exploration of new therapies. Efgartigimod, an IgG antibody Fc fragment, may offer a novel approach by enhancing IgG degradation. This study aims to assess its effectiveness and safety in GBS patients.
Data Highlights
Group
Good Improvement at Week 2
Good Improvement at Final Visit
TEAEs
Efgartigimod
37.5%
81.3%
18.8%
IVIg
0%
40.0%
50.0%
ISE
-
-
43.8%
Key Findings
52 patients were enrolled, receiving either IVIg, efgartigimod, or IVIg sequential efgartigimod (ISE).
The efgartigimod group showed a significantly higher rate of good improvement at week 2 (37.5% vs. 0%, p<0.01).
At the final visit, 81.3% of efgartigimod patients showed good improvement compared to 40.0% in the IVIg group (p=0.02).
The incidence of treatment-related adverse events was lower in the efgartigimod group (18.8%) compared to IVIg (50.0%) and ISE (43.8%).
The mean time to achieve GBS-DS ≤1 was shorter in the efgartigimod group (2.6 weeks) compared to IVIg (3.1 weeks).
Clinical Implications
Efgartigimod may represent a promising therapeutic option for GBS patients, showing improved efficacy and safety compared to traditional IVIg treatment. Further large-scale studies are needed to confirm these findings.
Conclusion
The study indicates the need for further research to establish the efficacy and safety of efgartigimod in GBS patients.
